Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 5/20 | 0.33 |
| ▸ | MME | P08473 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27205923 | 0.87 | CPB2 (0.37) | CPB2ACEMMEKDM4EMAPT | |
| SCHEMBL27191518 | 0.87 | CPB2 (0.37) | CPB2ACEMMEKDM4EMAPT | |
| SCHEMBL31234077 | 0.77 | KDM4E (0.53) | ACEKDM4EMAPTTHRBALOX15 | |
| Dacisteine SCHEMBL2402188 | 0.76 | MAPT (0.55) | CPB2ACEMMEKDM4EMAPT | |
| Dacisteine SCHEMBL1814125 | 0.76 | MAPT (0.55) | CPB2ACEMMEKDM4EMAPT | |
| SCHEMBL20122455 | 0.74 | ACE (0.48) | CPB2ACEMMEKDM4EMAPT | |
| SCHEMBL5921691 | 0.73 | PPARA (0.53) | ACESMN1; SMN2PPARGPPARA | |
| SCHEMBL13640190 | 0.73 | PPARA (0.53) | ACESMN1; SMN2PPARGPPARA | |
| SCHEMBL11337774 | 0.73 | CPB2 (0.36) | CPB2ACEMMEKDM4EMAPT | |
| SCHEMBL6692318 | 0.73 | PPARA (0.53) | ACESMN1; SMN2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688734-A1 | CYSTEINE DERIVATIVES FOR THE TREATMENT OF PRESBYOPIA | Lento Bio, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260035345-A1 | N-PIVALOYLCYSTEINE DERIVATIVES FOR THE TREATMENT OF PRESBYOPIA | LENTO BIO, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| WO-2024243373-A1 | CYSTEINE DERIVATIVES FOR THE TREATMENT OF PRESBYOPIA | LENTO BIO, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035345-A1 | N-PIVALOYLCYSTEINE DERIVATIVES FOR THE TREATMENT OF PRESBYOPIA | CRYAB, CRYAA, CRYZ | CPB2 764/4885ACE 2448/4885MME 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.